Coronavirus: Immunotherapy

(asked on 24th May 2021) - View Source

Question to the Department of Health and Social Care:

To ask Her Majesty's Government whether they intend to order monoclonal antibody therapies as an alternative to COVID-19 vaccines; and if so, whether they plan to do so before AstraZeneca reports the findings of its PROVENT study.


Answered by
Lord Bethell Portrait
Lord Bethell
This question was answered on 2nd June 2021

The Therapeutics Taskforce continues to monitor a range of COVID-19 therapeutics, including monoclonal antibodies, aimed at different stages of the treatment pathway. There has been a collaboration with the Vaccines Taskforce to assess the potential of neutralising monoclonal antibodies to provide passive immunity as an alternative to COVID-19 vaccines. We continue to work closely with the cross-agency group RAPID C-19, to assess evidence from clinical trials and delivery to patients, following regulatory approval.

We are in contact with a number of manufacturers to ensure that United Kingdom patients have access to COVID-19 therapeutics as evidence continues to emerge. Clinical trials, such as AstraZeneca’s PROVENT study, will be crucial in providing evidence as to which treatments are most effective.

Reticulating Splines